vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and ONESPAWORLD HOLDINGS Ltd (OSW). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $242.1M, roughly 1.2× ONESPAWORLD HOLDINGS Ltd). ONESPAWORLD HOLDINGS Ltd runs the higher net margin — 5.0% vs -45.7%, a 50.7% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 11.5%). ONESPAWORLD HOLDINGS Ltd produced more free cash flow last quarter ($14.9M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 7.1%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
GH vs OSW — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $242.1M |
| Net Profit | $-128.5M | $12.1M |
| Gross Margin | 64.6% | — |
| Operating Margin | -43.0% | 6.8% |
| Net Margin | -45.7% | 5.0% |
| Revenue YoY | 39.4% | 11.5% |
| Net Profit YoY | -15.8% | -16.2% |
| EPS (diluted) | $-1.01 | $0.12 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $242.1M | ||
| Q3 25 | $265.2M | $258.5M | ||
| Q2 25 | $232.1M | $240.7M | ||
| Q1 25 | $203.5M | $219.6M | ||
| Q4 24 | $201.8M | $217.2M | ||
| Q3 24 | $191.5M | $241.7M | ||
| Q2 24 | $177.2M | $224.9M | ||
| Q1 24 | $168.5M | $211.2M |
| Q4 25 | $-128.5M | $12.1M | ||
| Q3 25 | $-92.7M | $24.3M | ||
| Q2 25 | $-99.9M | $19.9M | ||
| Q1 25 | $-95.2M | $15.3M | ||
| Q4 24 | $-111.0M | $14.4M | ||
| Q3 24 | $-107.8M | $21.6M | ||
| Q2 24 | $-102.6M | $15.8M | ||
| Q1 24 | $-115.0M | $21.2M |
| Q4 25 | 64.6% | — | ||
| Q3 25 | 64.7% | — | ||
| Q2 25 | 65.0% | — | ||
| Q1 25 | 63.3% | — | ||
| Q4 24 | 61.6% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 59.1% | — | ||
| Q1 24 | 61.2% | — |
| Q4 25 | -43.0% | 6.8% | ||
| Q3 25 | -37.3% | 10.2% | ||
| Q2 25 | -45.9% | 9.2% | ||
| Q1 25 | -54.6% | 7.7% | ||
| Q4 24 | -62.4% | 7.9% | ||
| Q3 24 | -61.3% | 10.3% | ||
| Q2 24 | -56.8% | 8.4% | ||
| Q1 24 | -59.2% | 8.0% |
| Q4 25 | -45.7% | 5.0% | ||
| Q3 25 | -35.0% | 9.4% | ||
| Q2 25 | -43.0% | 8.3% | ||
| Q1 25 | -46.8% | 7.0% | ||
| Q4 24 | -55.0% | 6.6% | ||
| Q3 24 | -56.3% | 8.9% | ||
| Q2 24 | -57.9% | 7.0% | ||
| Q1 24 | -68.2% | 10.0% |
| Q4 25 | $-1.01 | $0.12 | ||
| Q3 25 | $-0.74 | $0.23 | ||
| Q2 25 | $-0.80 | $0.19 | ||
| Q1 25 | $-0.77 | $0.15 | ||
| Q4 24 | $-0.90 | $0.13 | ||
| Q3 24 | $-0.88 | $0.20 | ||
| Q2 24 | $-0.84 | $0.15 | ||
| Q1 24 | $-0.94 | $0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $16.3M |
| Total DebtLower is stronger | $1.5B | $84.0M |
| Stockholders' EquityBook value | $-99.3M | $542.6M |
| Total Assets | $2.0B | $707.1M |
| Debt / EquityLower = less leverage | — | 0.15× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $16.3M | ||
| Q3 25 | $580.0M | $29.6M | ||
| Q2 25 | $629.1M | $35.0M | ||
| Q1 25 | $698.6M | $22.6M | ||
| Q4 24 | $525.5M | $57.4M | ||
| Q3 24 | $585.0M | $48.8M | ||
| Q2 24 | $933.7M | $62.5M | ||
| Q1 24 | $1.0B | $65.4M |
| Q4 25 | $1.5B | $84.0M | ||
| Q3 25 | $1.1B | $85.2M | ||
| Q2 25 | $1.1B | $96.2M | ||
| Q1 25 | $1.1B | $97.4M | ||
| Q4 24 | $1.1B | $98.6M | ||
| Q3 24 | — | $98.7M | ||
| Q2 24 | — | $123.8M | ||
| Q1 24 | — | $138.6M |
| Q4 25 | $-99.3M | $542.6M | ||
| Q3 25 | $-354.5M | $552.8M | ||
| Q2 25 | $-305.5M | $548.3M | ||
| Q1 25 | $-250.8M | $530.6M | ||
| Q4 24 | $-139.6M | $554.5M | ||
| Q3 24 | $-60.1M | $540.1M | ||
| Q2 24 | $-1.6M | $532.7M | ||
| Q1 24 | $68.3M | $515.5M |
| Q4 25 | $2.0B | $707.1M | ||
| Q3 25 | $1.3B | $732.6M | ||
| Q2 25 | $1.3B | $731.8M | ||
| Q1 25 | $1.3B | $708.7M | ||
| Q4 24 | $1.5B | $746.4M | ||
| Q3 24 | $1.5B | $734.0M | ||
| Q2 24 | $1.6B | $756.8M | ||
| Q1 24 | $1.7B | $763.6M |
| Q4 25 | — | 0.15× | ||
| Q3 25 | — | 0.15× | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.18× | ||
| Q4 24 | — | 0.18× | ||
| Q3 24 | — | 0.18× | ||
| Q2 24 | — | 0.23× | ||
| Q1 24 | — | 0.27× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $20.0M |
| Free Cash FlowOCF − Capex | $-54.2M | $14.9M |
| FCF MarginFCF / Revenue | -19.3% | 6.2% |
| Capex IntensityCapex / Revenue | 9.9% | 2.1% |
| Cash ConversionOCF / Net Profit | — | 1.65× |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $68.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $20.0M | ||
| Q3 25 | $-35.4M | $33.2M | ||
| Q2 25 | $-60.3M | $20.3M | ||
| Q1 25 | $-62.7M | $10.1M | ||
| Q4 24 | $-64.5M | $16.6M | ||
| Q3 24 | $-51.1M | $28.6M | ||
| Q2 24 | $-94.0M | $18.7M | ||
| Q1 24 | $-30.3M | $15.0M |
| Q4 25 | $-54.2M | $14.9M | ||
| Q3 25 | $-45.8M | $27.6M | ||
| Q2 25 | $-65.9M | $17.6M | ||
| Q1 25 | $-67.1M | $8.4M | ||
| Q4 24 | $-83.4M | $13.2M | ||
| Q3 24 | $-55.3M | $27.5M | ||
| Q2 24 | $-99.1M | $17.6M | ||
| Q1 24 | $-37.2M | $13.7M |
| Q4 25 | -19.3% | 6.2% | ||
| Q3 25 | -17.3% | 10.7% | ||
| Q2 25 | -28.4% | 7.3% | ||
| Q1 25 | -33.0% | 3.8% | ||
| Q4 24 | -41.3% | 6.1% | ||
| Q3 24 | -28.9% | 11.4% | ||
| Q2 24 | -55.9% | 7.8% | ||
| Q1 24 | -22.1% | 6.5% |
| Q4 25 | 9.9% | 2.1% | ||
| Q3 25 | 3.9% | 2.2% | ||
| Q2 25 | 2.4% | 1.1% | ||
| Q1 25 | 2.2% | 0.8% | ||
| Q4 24 | 9.4% | 1.5% | ||
| Q3 24 | 2.2% | 0.5% | ||
| Q2 24 | 2.9% | 0.5% | ||
| Q1 24 | 4.1% | 0.6% |
| Q4 25 | — | 1.65× | ||
| Q3 25 | — | 1.36× | ||
| Q2 25 | — | 1.02× | ||
| Q1 25 | — | 0.66× | ||
| Q4 24 | — | 1.15× | ||
| Q3 24 | — | 1.33× | ||
| Q2 24 | — | 1.19× | ||
| Q1 24 | — | 0.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
OSW
| Services | $197.3M | 82% |
| Products | $44.8M | 18% |
